Reagan et al. [10] demonstrated in vivo that anti-sclerostin treatment delivered to MM-bearing mice was effective in increasing trabecular bone volumes by 46% and trabecular thickness by 30%, returning their bone volumes to similar levels of the non-tumour control mice and prevented further MBD. The gene discussed is SOST; the disease is Miyoshi myopathy.